Testicular cancer

Current Opinion in Oncology

Volumn 13, Issue 3, 2001, Pages 191-198

  Oliver, R T D ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM DERIVATIVE; VANADIUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CRYPTORCHISM; HISTOPATHOLOGY; HUMAN; KENYA; MALE; NON SEMINOMATOUS GERMINOMA; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TESTIS CANCER; X CHROMOSOME;

HUMANS; MALE; TESTICULAR NEOPLASMS;

EID: 0035031501     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200105000-00011     Document Type: Review

References (64)

1. 1 Opot E, Magoha G: Testicular cancer at Kenyatta National Hospital. East Afr Med J 2000, 77:80-85.
2. 2 Bhatia S, Abonour R, Porcu P, et al.: High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000, 18:3346-3351. Sixty-five patients treated in the 6 years between 1992 and 1998 with tandem high-dose treatment as initial salvage therapy, with 57% continuously disease free and 62% overall survival, set a new standard for future comparison.
3. 3 Armstrong L: It's Not About the Bike. London: Random House Pty Limited; 2000.
4. 4 Gascoigne P, Mason M, Roberts E: Factors affecting presentation and delay in patients with testicular cancer: results of qualiative study. Psychooncology 1999, 8:144-154.
5. 5 Oliver R: Chemotherapy in urology: testis cancer. In Comprehensive Urology. Edited by Weiss RM, George NJ, O'Reilly PM. London: Mosby International Ltd; 2001:673-678.
6. 6 Mulatero C, Brogan C, Oliver R: Advanced testicular cancer presenting with phlegmasia cerulea dolens. Postgrad Med J 2000, 76:234-236.
7. 7 Oliver R, Ong J, Blandy J, et al.: Testis conservation studies in germ cell cancer justified by improved primary chemotherapy response and reduced delay 1978-1994. Br J Urol 1996, 78:119-124.
8. 8 Aki F, CY Bilen, Tekin M, et al.: Is scrotal violation per se a risk factor for local relapse and metastases in stage 1 non-seminomatous testicular cancer. Urology 2000, 56:459-462.
9. 9 Bozcuk H, Ravi R, Turner B, et al.: Computed tomography 21 days after chemotherapy, three-dimensional estimates of metastatic volume and the need for surgery in patients with germ cell cancer. BJU Int 2000, 86:707-713.
10. 10 Fossa S, Bokemeter C, Gerl A, et al.: Treatment outcome of patients with brain metastases from malignant germ cell tumours. Cancer 1999, 85:988-997.
11. 11 Vijayaraghavan S, Brock C, Monson JP, et al.: Does the rapid response to cisplatin-based chemotherapy justify its use as primary treatment for intracranial germ cell tumours? Quart J Med 1993, 86:801-810.
12. 12 Javadpour N, Ozols RF, Anderson T, et al.: A randomized trial of cytoreductive surgery followed by chemotherapy versus chemotherapy alone in bulky stage testicular cancer with poor prognostic features. Cancer 1982, 50:2004-2010.
13. 13 Little M, Sayers E, Paul K, et al.: On surviving cancer, J R Soc Med 2000, 93:501-502.
14. 14 Swift S: Where it hurts. London: Judy Piatkus Publishers; 1983.
15. 15 Rilianawati, Kero J, Paukku T, et al.: Long-term testosterone treatment prevents gonadal and adrenai tumorigenesis of mice transgenic for the mouse inhibin-alpha subunit promoter/simian virus 40 T-antigen fusion gene. J Endocrinol 2000, 166:77-85. A transgenic mouse model was developed by using a 6-kb fragment of the inhibin-alpha subunit promoter fused with simian virus T-antigen coding sequence. These mice, by the age of 5 to 8 months, had a 100% incidence of Leydig cell tumors resulting from leutinizing hormone over stimulation, which was suppressed by testosterone supplements.
16. 02 decreased from 61.4 to 19.4 mmHg after 3 minutes and then took 10 minutes to recover when cycling stopped.
17. 6 sperm/mL).
18. 18 Jacobsen R, Bostofe E, Engholm G, et al.: Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study. Hum Reprod 2000, 15:1958-1961.
19. 6 sperm/mL.
20. 20 Weir H, Marrett L, Kreiger N, et al.: Pre-natal and peri-natal exposures and risk of testicular germ cell cancer. Int J Cancer 2000, 87:438-443.
21. 21 Ohlson C, Hardell L: Testicular cancer and occupational exposures with a focus on xenoestrogens in polyvinyl chloride plastics. Chemosphere 2000, 40:1277-1282.
22. 22 Guo Y, Hsu P, Hsu C, et al.: Semen quality after prenatal exposure to polychlorinated biphenyls and dibenzofurans. Lancet 2000, 356:1240-1241.
23. 23 Kommoss F, Oliva E, Bittinger F, et al.: Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol 2000, 31:1055-1061.
24. 24 Roelofs H, Manes T, Janszen T, et al.: Heterogeneity in alkaline phosphatase isozyme expression in human testicular germ cell tumours: an enzyme/immunohistochemical and molecular analysis. J Pathol 1999, 189:236-244. An important study showing that with availability of appropriate monoclonal antibodies it is now possible to separate tissue expression of germ cell-specific from placental-and tissue-nonspecific alkaline phosphatase, which should help improve diagnosis of seminoma.
25. 25 Dabare A, Nouri A, Cannell H, et al.: Profile of placental alkaline phosphatase expression in human malignancies: effect of tumour cell activation on alkaline phosphatase expession. Urol Int 1999, 63:168-174.
26. 26 Hautkappe A, Lu M, Mueller H, et al.: Detection of germ-cell tumour cells in the peripheral blood by nested reverse transcription-polymerase chain reaction for alpha-fetoprotein-messenger RNA and beta human chorionic gonadotrophin-messenger RNA, Cancer Res 2000, 60:3170-3174.
27. 27 Rapley E, Crockford G, Teare D, et al.: Localisation to Xq27 of a susceptibility gene for testicular germ cell tumours. Nat Genet 2000, 24:197-200. The first definitive gene linked to genetic susceptibility to testis cancer. It has been shown to be predominantly involved in susceptibility in those with cryptorchidism.
28. 28 Looijenga L, Rosenberg C, Gutp Rv, et al.: Comparative genomic hybridization of microdissected samples from different stages in the development of a seminoma and a non-seminoma. J Pathol 2000, 191:187-192.
29. 29 Faulker S, Leigh D, Oosterhuis J, et al.: Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: evidence suggestive of the linear progression model. Brit J Cancer 2000, 83:729-736.
30. 30 Rosenberg C, Shut T, Mostert M, et al.: Chromosomal gains and losses in testicular germ cell tumours of adolescents and adults investigated by a modified comparative genomic hybridization approach. Lab Invest 1999, 79:1447-1451.
31. 31 Bartkova J, Thullberg M, Meyts ER-D, et al.: Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours. Int J Cancer 2000, 85:370-375. The first report that loss of p18INK4C is a molecular genetic marker involved in cell regulation involved in progression from carcinoma in situ to invasive cancer.
32. 32 Bartkova J, Thullberg M, Meyts ER-D, et al.: Lack of p19INK4d in human testicular germ cell tumours contrasts with high expression during normal spermatogenesis. Oncogene 2000, 19:4146-4150.
33. 33 Motzer R, Sheinfeld J, Mazumdar M, et al.: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000, 18:2413-2418.
34. 34 Mariani T, Tong W, Bosl G: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumour patients. J Clin Oncol 2000, 18:1173-1180.
35. 35 Shamash J, Oliver R, Ong J, et al.: 60% salvage rate for germ cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy. Ann Oncol 1999, 10:685-692.
36. 36 Bono JD, Paul J, Simpson A, et al.: Improving the outcome of salvage treatment for non-seminomatous germ cell tumours. Brit J Cancer 2000, 83:426-430.
37. 37 Porcu P, Bhatia S, Sharma M, et al.: Results of treatment after relapse from high dose chemotherapy (HDCT) in germ cell tumours. J Clin Oncol 1999, 18:1181-1186. An important overview demonstrating lack of response to salvage treatment of patients failing high-dose regimens with only 4.9% of 101 patients showing benefit, mainly from oral etoposide.
38. 38 Judson I, Kelland L: New developments and approaches in the platinum arena. Drugs 2000, 4:29-36.
39. 39 Ghosh P, D'Cruz O, Narla R, et al.: Apoptosis-inducing vanadocene compounds against human testicular cancer. Clin Cancer Res 2000, 6:1536-1545.
40. 40 Shamash J, Oliver R, Gallagher C, et al.: Pre-induction LDH as a prognostic factor for outcome of high-dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Brit J Cancer 2000, 82:2002-2023. A reminder of the importance of lactic dehydrogenase as a predictor of poor outcome even in patients undergoing high-dose chemotherapy as salvage.
41. 41 Ganjoo K, Rieger K, Kesler K, et al.: Results of modern therapy for patients with mediastinal non-seminomatous germ cell tumours. Cancer 2000, 85:1051-1056. Results from a modern series of patients with mediastinal germ cell tumors confirming their poor outlook with 28 of 39 (72%) complete response status but only 16 of 39 (41%) durable response.
42. 42 Amato R, Millikan R, Daliani D, et al.: Cyclophosphamide and carboplatin and selective consolidation in advanced seminoma. Clin Cancer Res 2000, 6:72-77.
43. 2 were associated with an 8.6% relapse rate.
44. 44 Francis R, Bower M, Brunstrom G, et al.: Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000, 36:1925-1932. An important paper on 5-year follow-up of 303 stage 1 patients followed with meticulous tumor marker surveillance with 70 relapses, 68 of which were salvaged for an overall survival of 99%.
45. 45 Sweeney C, Hermans B, Heilman D, et al.: Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J Clin Oncol 2000, 18:358-362.
46. 46 Hermans B, Sweeney C, Foster R, et al.: Risk of systemic metastases in clinical stage I non-seminoma germ cell testis managed by retroperitoneal lymph node dissection. J Urol 2000, 163:1721-1724.
47. 47 Studer U, Burkhard F, Sonntag R: Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage 1 non-seminomatous germ cell tumour. J Urol 2000, 163:1785-1787. Late follow-up, demonstrating durability of relapse-free survival in high-risk stage 1 nonseminoma managed with adjuvant chemotherapy.
48. 48 Hendry W, Norman A, Nicholls J, et al.: Abdominal relapse in stage I non-seminomatous germ cell tumours of the testis managed by surveillance or with adjvant chemotherapy. BJU Int 2000, 86:89-93.
49. 49 Behnia M, Foster R, Einhorn L, et al.: Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indian University experience. Eur J Cancer 2000, 36:472-475.
50. 50 Weissbach L, Maatz RB, Flechtner H, et al.: RPLND or primary chemotherapy in clincal stage IIA/B non-seminomatous germ cell tumours? Results of a prospective multicentre trial including quality of life assessment. Eur Urol 2000, 37:582-594. An underpowered but important study comparing use of retroperitoneal lymph node dissection versus chemotherapy for clinical stage 2. The authors do not comment on the significantly lower incidence of loss of fertility after chemotherapy-induced down staging presurgery.
51. 51 Beck S, Ulbright T, Foster R: A benign para-aortic lymph node of histologically proved follicular hyperplasia mimicking metastastic germ cell cancer. J Urol 2000, 163:1520-1521.
52. 52 Hain S, O'Doherty M, Timothy A: Fluorodeoxygluscose positron-emission tomography in the evaluation of germ cell tumours at relapse. Brit J Cancer 2000, 83:863-869.
53. 53 Janetschek G, Hobisch A, Hittmair A, et al.: Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma. J Urol 1999, 161:477-481.
54. 54 Engeler D, Hosli P, John H, et al.: Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. Urology 2000, 56:144-148.
55. 55 Tekin A, Aygum Y, Aki F, et al.: Bilateral germ cell cancer of the testis: a report of 11 patients with a long term follow up. BJU Int 2000, 85:864-868.
56. 56 Low J, Perrin L, Crandon A, et al.: Conservation surgery to preserve ovarian function in patients with malignant ovarian germ cell tumours: a review of 74 cases. Cancer 2000, 89:391-398.
57. 57 Res U, Res P, Kastelic D, et al.: Birth after treatment of a male with seminoma and azoospermia with cryopreserved-thawed testicular tissue. Hum Reprod 2000, 15:861-864. An important anecdote that needs to be remembered by all doing orchidectomy on a man with a tumor in a solitary testis, because it demonstrates that adequate sperm can be harvested for conception at a later date.
58. 58 Dotsch M, Brauers A, Buttner R, et al.: Malignant germ cell tumour of the contralateral testis after radiotherapy for testicuiar intraepithelial neoplasia. J Urol 2000, 164:452-453. An equally important anecdote, because it reports the first case of relapse after radiation for carcinoma in situ of testis.
59. 59 Cappelen T, Fossa S, Stenwig A, et al.: False negative biopsy for testicular intraepithelial neoplasia and high risk features for testicuiar cancer. Acta Oncol 2000, 39:105-109.
60. 60 Travis L, Andersson M, Gospodarowicz M, et al.: Treatment associated leukemia following testicuiar cancer. J Natl Cancer Inst 2000, 92:1165-1171. A possibly worrying association between cisplatin dose and leukemia, but despite the large database, the small number of cases fails to make it possible to separate out the contribution of etoposide to these cases.
61. 61 Hernandez A, Fossa S, Brogger A, et al.: Chromosome aberrations after etoposide containing cisplatin-based chemotherapy for malignant germ cell tumours. Ann Oncol 2000, 11:897-898.
62. 62 Meinardi M, Gietema J, Graaf Wvd, et al.: Cardiovascular morbidity in long term survivors of metastatic testicuiar cancer. J Clin Oncol 2000, 18:1725-1732. An important reminder that because the average testis cancer patient has a 40-year life expectancy after treatment, we must consider the sevenfold increased risk of cardiovascular events in designing future trials.
63. 63 Gietma J, Meinardi M, Messerschmidt J, et al.: Circulating plasma platinum more than 10 years after cisplatin treatment for testicuiar cancer. Lancet 2000, 355:1075-1076. These authors define a possible surrogate end point to improve documenting risk of late events. They demonstrate platinum in plasma on follow-up at 20 years after treatment.
64. 64 Marchessault J: Rethinking non-seminomatous testicular cancer in U.S. Air Force pilots: case presentation and literature review. Aviat Space Environ Med 2000, 71:61-64.